Company intelligence / Profile preview
UPPthera
Daegu, South Koreauppthera.com ↗
- Ownership
- Private
- Employees
- ~19
- Development stage
- Other
01
Overview
UPPthera has developed a pipeline of drug candidates using targeted protein degradation technology (PROTACs) with a focus on metabolic diseases and several cancer types. The company has filed at least 15 patents related to protein degradation compounds and has demonstrated success in hit-finding against undruggable targets through collaborations. No late-stage or commercialized products are reported as of now
- Therapeutic areas
- Metabolic DisordersCardiovascularOncology
- Modalities
- Proteolysis-targeting chimera therapySmall molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
HitGen Inc. – collaboration for PROTAC research and hit-finding against undruggable targets
Beyond the preview
Go deeper on UPPthera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UPPthera.